Acquisition
Zenex buys majority stake in VievePharm
By Abha Lohia · Editor ·
Zenex Animal Health: revenue and funding and every story →
Ahmedabad
- Zenex took a controlling share in VievePharm, a Dutch maker of natural animal nutrition products, for an undisclosed price
- The deal gives the Indian firm a factory and sales base in Western Europe, where rules on antibiotics are tightening
- VievePharm's bolus (large slow-release tablet) know-how for minerals, vitamins and udder health will join Zenex's global range
What happened
- Zenex Animal Health India bought a majority stake in VievePharm of the Netherlands.
- VievePharm makes plant-based feed formulations for livestock, horses and pets.
- It is based in Enter, in the Netherlands.
- The EU wants veterinary antibiotic sales cut by 50% by 2030 from 2018 levels.
The numbers around it
Zenex Animal Health has 1 funding rounds in StopDown's archive.
| When | Round | Amount | Led by |
|---|---|---|---|
| 6 December 2021 | Growth equity | $52.5 million | Undefined |
Terms in this story
- Majority stake acquisition: A majority stake deal is an acquisition in which the buyer takes more than half of a company, often 51%, and agrees on how the remaining shares may be bought later. It gives the buyer control now, keeps the founders invested, and spreads the price over time.
Everything on Zenex Animal Health → · All startup news on 27 February 2026 →
Is this Zenex Animal Health? Get your “Featured on StopDown” badge →